Takeda Pharmaceutical Co. $TAK Shares Sold by Beverly Hills Private Wealth LLC

Beverly Hills Private Wealth LLC lessened its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 8.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,704 shares of the company’s stock after selling 2,075 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Takeda Pharmaceutical were worth $351,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. acquired a new stake in Takeda Pharmaceutical during the first quarter worth about $51,049,000. Goldman Sachs Group Inc. raised its stake in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares during the period. ABC Arbitrage SA acquired a new stake in Takeda Pharmaceutical during the first quarter worth about $4,994,000. Crossmark Global Holdings Inc. raised its stake in Takeda Pharmaceutical by 88.5% during the first quarter. Crossmark Global Holdings Inc. now owns 396,833 shares of the company’s stock worth $5,901,000 after acquiring an additional 186,349 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in Takeda Pharmaceutical during the first quarter worth about $2,361,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $14.07 on Tuesday. The firm’s 50 day moving average is $14.81 and its two-hundred day moving average is $14.75. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69. The firm has a market capitalization of $44.75 billion, a P/E ratio of 46.88 and a beta of 0.21. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on TAK shares. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. Weiss Ratings reiterated a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, October 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.